Researchers explored this question at ASH and shared data suggesting genomic instability in tumors with high TMB likely enables them to hide from immune attack.

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...

RNA-based therapeutics face challenges in bioanalysis, with experts recommending strategies to improve LC–MS performance and standardize ADME and DMPK practices. GLP-1 therapies require careful ...

Single-cell sequencing provides unprecedented detail into cell-to-cell variability, uncovering key biological mechanisms in ...